Skip to main content

OnKure Therapeutics, Inc.

corporate_fare Company Profile

OnKure Therapeutics, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed OKUR - Latest Insights

OKUR
Apr 21, 2026, 4:16 PM EDT
Filing Type: DEFA14A
Importance Score:
7
OnKure Proposes 8% Equity Plan Increase and Removes Evergreen Limit Ahead of Annual Meeting
Sentiment: Neutral
View Wiseek Article
OKUR
Apr 21, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
7
OnKure Therapeutics Seeks Shareholder Approval for 8% Equity Plan Increase and Evergreen Provision Changes
Sentiment: Neutral
View Wiseek Article
OKUR
Apr 07, 2026, 9:14 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Access Industries Takes 19.99% Stake in OnKure Therapeutics, Secures Board Seat in $40M Strategic Investment
Sentiment: Positive
View Wiseek Article
OKUR
Mar 30, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
9
OnKure Secures $150M Private Placement at Premium, Resolving Going Concern Doubt
Sentiment: Positive
View Wiseek Article
OKUR
Mar 27, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Oversubscribed $150M Private Placement Secures OnKure's Future, Funds Key Drug Programs
Sentiment: Positive
View Wiseek Article
OKUR
Mar 12, 2026, 4:15 PM EDT
Source: Wiseek News
Importance Score:
9
Zero Revenue, $4.40 Loss Per Share: OnKure's 10-K Reveals Deepening Financial Woes
Sentiment: Negative
View Wiseek Article
OKUR
Mar 12, 2026, 4:10 PM EDT
Filing Type: 10-K
Importance Score:
9
OnKure Therapeutics Reports Substantial Loss, Raises Going Concern Doubt, and Initiates $16M ATM Program
Sentiment: Negative
View Wiseek Article